Search

Your search keyword '"Fan, Chao-Yueh"' showing total 21 results
Start Over Author "Fan, Chao-Yueh"
21 results on '"Fan, Chao-Yueh"'

7. Review of current perspectives on low-energy X-ray intraoperative radiotherapy in early stage breast cancer

Author

Dai, Yang-Hong, primary, Chen, Yu-Jen, additional, Lin, Chun-Shu, additional, Lin, Kuen-Tze, additional, Huang, Wen-Yen, additional, Chen, Chang-Ming, additional, Su, Yu-Fu, additional, Fan, Chao-Yueh, additional, Lo, Chen-Hsiang, additional, Yang, Yen-Fu, additional, Tsao, Chih-Cheng, additional, Liu, Ming-Yueh, additional, Shen, Po-Chien, additional, Chao, Hsing-Lung, additional, and Chao, Kun-San, additional

Published
2019
Full Text
View/download PDF

16. Treatment outcomes with whole‐field versus split‐field intensity‐modulated radiotherapy for patients with nasopharyngeal carcinoma.

Author

Lin, Chun‐Shu, Chen, Yuan‐Wu, Liu, Shao‐Cheng, Tsao, Chih‐Cheng, Lin, Kuen‐Tze, Lee, Steve P., Fan, Chao‐Yueh, Liu, Ming‐Yueh, Shen, Po‐Chien, and Jen, Yee‐Min

Subjects
INTENSITY modulated radiotherapy, TREATMENT effectiveness
Abstract

Background: The purpose of this study was to present our comparison of the clinical outcome of patients with nasopharyngeal carcinoma (NPC) treated with whole‐field intensity‐modulated radiotherapy (whole‐field‐IMRT) or split‐field‐IMRT. Methods: We retrospectively studied 388 patients with M0 NPC. The median lower neck doses were 50 Gy in 1.35 Gy/fractions for the 240 whole‐field‐IMRT patients, and 50.4 Gy in 1.8 to 2.0 Gy/fractions for the 148 split‐field‐IMRT patients. Results: The IMRT technique did not affect the overall survival (OS; P =.077) and locoregional control (P =.231) rates. However, the split‐field‐IMRT group had more locoregional recurrences at the whole neck (P =.005) but not at the nasopharynx (P =.968) or the lower neck (P =.485). The patients treated with split‐field‐IMRT (43.2%) had more grade III neck fibrosis than the patients who received whole‐field‐IMRT (18.3%; P <.001). Only 1 patient had temporal lobe necrosis in our study. Conclusion: Our study shows that whole‐field‐IMRT using a lower dose/fraction for the lower neck results in at least comparable locoregional control and less fibrosis compared to conventional fraction with split‐field‐IMRT. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

20. Stereotactic Ablative Radiotherapy for Patients with Unresectable or Medically Inoperable Cholangiocarcinoma

Author

Liu, Ming-Yueh, Lo, Cheng-Hsiang, Lin, Chun-Shu, Chao, Hsing-Lung, Yang, Jen-Fu, Lin, Kuen-Tze, Fan, Chao-Yueh, Su, Yu-Fu, and Huang, Wen-Yen

Abstract

Purpose The role of stereotactic ablative radiotherapy (SABR) in patients with unresectable or medically inoperable cholangiocarcinoma remains unclear. We examined the efficacy and safety of SABR in this group of patients.Methods From January 2008 to December 2014, 15 patients with 17 lesions were included in this study. The lesions included 14 intrahepatic, 1 hilar, and 2 distal bile duct tumors. Three patients were classified as medically inoperable because of old age or multiple comorbidities. Tumors measured 0.8-13 cm (median, 3.6 cm). The median prescribed dose was 45 Gy delivered in 5 fractions over 5 consecutive days.Results The median follow-up period for surviving patients was 29.9 months. Objective responses were observed for 10 of 17 tumors (58.8%), including 3 complete responses (17.6%). The median survival duration was 12.6 months, and the 1- and 2-year overall survival rates were 50.3% and 14.4%, respectively. The 1- and 2-year in-field failure-free rates were 61.5% and 30.8%, respectively. For patients with biologically effective doses (BEDs) exceeding 75 Gy10, the 1- and 2-year overall survival rates were 58.3% and 33.3%, respectively, compared to 20.0% and 0%, respectively for those with BEDs lower than 75 Gy10.Radiation-induced liver disease did not develop in any patient. Acute toxicities were generally mild and tolerable.Conclusions Stereotactic ablative radiotherapy could be an alternative treatment for unresectable or medically inoperable cholangiocarcinoma. Further dose escalation may be considered to optimize local control.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results